What was the market valuation of the US creutzfeldt jakob-disease market in 2024?

The market valuation was $168.0 Million in 2024. Read More

What is the projected market valuation for the US creutzfeldt jakob-disease market by 2035?

The projected valuation for 2035 is $362.7 Million. Read More

What is the expected CAGR for the US creutzfeldt jakob-disease market during the forecast period 2025 - 2035?

The expected CAGR during this period is 7.25%. Read More

Which companies are key players in the US creutzfeldt jakob-disease market?

Key players include Grifols, Biogen, Eli Lilly and Company, Novartis, Roche, Pfizer, Bristol-Myers Squibb, and Amgen. Read More

What are the market segments for the US creutzfeldt jakob-disease market?

Market segments include type, diagnosis method, treatment approach, and end user. Read More

What was the valuation for sporadic Creutzfeldt-Jakob Disease in 2024?

The valuation for sporadic Creutzfeldt-Jakob Disease ranged from $80.0 Million to $180.0 Million. Read More

How much is the valuation for symptomatic treatment expected to be in the US creutzfeldt jakob-disease market?

The valuation for symptomatic treatment is projected to range from $88.0 Million to $172.7 Million. Read More

What is the expected valuation for cerebrospinal fluid tests in the market?

The expected valuation for cerebrospinal fluid tests ranges from $50.0 Million to $110.0 Million. Read More

Which end user segment is projected to have the highest valuation in 2035?

Research institutes are projected to have the highest valuation, ranging from $72.0 Million to $149.7 Million. Read More

What is the projected valuation range for experimental therapies in the US creutzfeldt jakob-disease market?

The projected valuation for experimental therapies ranges from $30.0 Million to $80.0 Million. Read More

US Creutzfeldt Jakob Disease Market

ID: MRFR/Pharma/18365-HCR

100 Pages

Vikita Thakur

Last Updated: April 06, 2026

US Creutzfeldt-Jakob Disease Market Research Report By Type (Sporadic Creutzfeldt-Jakob Disease, Familial Creutzfeldt-Jakob Disease, Iatrogenic Creutzfeldt-Jakob Disease, Variant Creutzfeldt-Jakob Disease), By Diagnosis Method (Electroencephalogram, Magnetic Resonance Imaging, Cerebrospinal Fluid Tests, Brain Biopsy), By Treatment Approach (Supportive Care, Experimental Therapies, Symptomatic Treatment) and By End User (Hospitals, Diagnostic Laboratories, Research Institutes) - Growth & Industry Forecast 2025 To 2035

US Creutzfeldt Jakob Disease Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)7.25%

2024 Market Size$ 168 Million

2025 Market Size$ 180.18 Million

2035 Market Size$ 362.7 Million

Key Players

Grifols

Biogen

Eli Lilly and Company

Novartis

Roche

Pfizer

Trends

Advancements in Diagnostic Techniques
Increased Research Funding
Collaboration Among Stakeholders

Opportunities

Regulatory Support for Research
Increased Awareness and Education
Growing Demand for Diagnostic Services

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type (USD Million)
  1. 4.1.1 Sporadic Creutzfeldt-Jakob Disease
  2. 4.1.2 Familial Creutzfeldt-Jakob Disease
  3. 4.1.3 Iatrogenic Creutzfeldt-Jakob Disease
  4. 4.1.4 Variant Creutzfeldt-Jakob Disease
2. 4.2 Healthcare, BY Diagnosis Method (USD Million)
  1. 4.2.1 Electroencephalogram
  2. 4.2.2 Magnetic Resonance Imaging
  3. 4.2.3 Cerebrospinal Fluid Tests
  4. 4.2.4 Brain Biopsy
3. 4.3 Healthcare, BY Treatment Approach (USD Million)
  1. 4.3.1 Supportive Care
  2. 4.3.2 Experimental Therapies
  3. 4.3.3 Symptomatic Treatment
4. 4.4 Healthcare, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Diagnostic Laboratories
  3. 4.4.3 Research Institutes
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Grifols (ES)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Biogen (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Eli Lilly and Company (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Roche (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bristol-Myers Squibb (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Amgen (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS METHOD
4. 6.4 US MARKET ANALYSIS BY TREATMENT APPROACH
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF HEALTHCARE
9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
12. 6.12 HEALTHCARE, BY TYPE, 2024 (% SHARE)
13. 6.13 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 (% SHARE)
15. 6.15 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
16. 6.16 HEALTHCARE, BY TREATMENT APPROACH, 2024 (% SHARE)
17. 6.17 HEALTHCARE, BY TREATMENT APPROACH, 2024 TO 2035 (USD Million)
18. 6.18 HEALTHCARE, BY END USER, 2024 (% SHARE)
19. 6.19 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT APPROACH, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Creutzfeldt Jakob Disease Market Segmentation

US Creutzfeldt Jakob Disease Market By Type (USD Million, 2025-2035)

Sporadic Creutzfeldt-Jakob Disease
Familial Creutzfeldt-Jakob Disease
Iatrogenic Creutzfeldt-Jakob Disease
Variant Creutzfeldt-Jakob Disease

US Creutzfeldt Jakob Disease Market By Diagnosis Method (USD Million, 2025-2035)

Electroencephalogram
Magnetic Resonance Imaging
Cerebrospinal Fluid Tests
Brain Biopsy

US Creutzfeldt Jakob Disease Market By Treatment Approach (USD Million, 2025-2035)

Supportive Care
Experimental Therapies
Symptomatic Treatment

US Creutzfeldt Jakob Disease Market By End User (USD Million, 2025-2035)

Hospitals
Diagnostic Laboratories
Research Institutes

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”